An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler With e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants With Asthma (4 to 11 Years Old)
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Albuterol sulfate/fluticasone propionate (Primary) ; Fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Teva Branded Pharmaceutical Products R&D
- 29 Oct 2024 Status changed from recruiting to completed.
- 17 Jun 2024 Planned End Date changed from 14 Dec 2024 to 25 Nov 2024.
- 17 Jun 2024 Planned primary completion date changed from 6 Nov 2024 to 16 Oct 2024.